Preclinical Evaluation of 4-Methylthiobutyl Isothiocyanate on Liver Cancer and Cancer Stem Cells with Different p53 Status

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Lamy, Evelyn ^a   Hertrampf, Anke ^a,b   Herz, Corinna ^a   Schüler, Julia ^c   Erlacher, Miriam ^a   Bertele, Daniela ^a   Bakare, Adekunle ^d   Wagner, Meike ^e   Weiland, Timo ^f   Lauer, Ulrich ^f   Drognitz, Oliver ^a   Huber, Roman ^a   Rohn, Sascha ^g   Giesemann, Torsten ^c   Mersch Sundermann, Volker ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c CHARLES RIVER LABORATORIES   (United States)

^d UNIVERSITY OF IBADAN   (Nigeria)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERUCIN; PROTEIN BCL 2; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER STEM CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TOLERABILITY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; MOUSE; NONHUMAN;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOBLOTTING; ISOTHIOCYANATES; LIVER NEOPLASMS; MICE; MICE, NUDE; MUTATION; NEOPLASTIC STEM CELLS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880969626     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070846     Document Type: Article

References (52)

1. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD, (2008) Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 14: 4300-4308.
2. Greten TF, Blum HE, Manns MP, Geissler M, (2006) [Treatment of hepatocellular carcinoma]. Z Gastroenterol 44: 43-49.
3. Chan KT, Lung ML, (2004) Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother Pharmacol 53: 519-526.
4. Levine AJ, (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
5. Nault JC, Zucman-Rossi J, (2011) Genetics of hepatobiliary carcinogenesis. Semin Liver Dis 31: 173-187.
6. Jones RJ, Matsui WH, Smith BD, (2004) Cancer stem cells: are we missing the target? J Natl Cancer Inst 96: 583-585.
7. Carr BI, (2004) Hepatocellular carcinoma: current management and future trends. Gastroenterology 127: S218-224.
8. Conaway CC, Yang YM, Chung FL, (2002) Isothiocyanates as cancer chemopreventive agents: their biological activities and metabolism in rodents and humans. Curr Drug Metab 3: 233-255.
9. Fimognari C, Lenzi M, Hrelia P, (2009) Apoptosis induction by sulfur-containing compounds in malignant and nonmalignant human cells. Environ Mol Mutagen 50: 171-189.
10. Li Y, Zhang T, Korkaya H, Liu S, Lee HF, et al. (2010) Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res 16: 2580-2590.
11. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, et al. (2009) Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 58: 949-963.
12. Yeh CT, Yen GC, (2005) Effect of sulforaphane on metallothionein expression and induction of apoptosis in human hepatoma HepG2 cells. Carcinogenesis 26: 2138-2148.
13. Rose P, Whiteman M, Huang SH, Halliwell B, Ong CN, (2003) beta-Phenylethyl isothiocyanate-mediated apoptosis in hepatoma HepG2 cells. Cell Mol Life Sci 60: 1489-1503.
14. Lamy E, Mersch-Sundermann V, (2009) MTBITC mediates cell cycle arrest and apoptosis induction in human HepG2 cells despite its rapid degradation kinetics in the in vitro model. Environ Mol Mutagen 50: 190-200.
15. Lamy E, Crossmann C, Saeed A, Schreiner PR, Kotke M, et al. (2009) Three structurally homologous isothiocyanates exert "Janus" characteristics in human HepG2 cells. Environ Mol Mutagen 50: 164-170.
16. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J, (1982) Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42: 3858-3863.
17. Roth T, Burger AM, Dengler W, Willmann H, Fiebig HH (1999) Human tumor cell lines demonstrating the characteristics of patient tumors as useful models for anticancer drug screening; Fiebig HH, AM B, editors: Contrib Oncol. 145-156 p.
18. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, et al. (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 65: 6207-6219.
19. Guguen-Guillouzo C, Bourel M, Guillouzo A, (1986) Human hepatocyte cultures. Prog Liver Dis 8: 33-50.
20. Strom S, Michalopoulos G, (1982) Mutagenesis and DNA binding of benzo(a)pyrene in cocultures of rat hepatocytes and human fibroblasts. Cancer Res 42: 4519-4524.
21. Zimmermann M, Armeanu S, Smirnow I, Kupka S, Wagner S, et al. (2009) Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses. Int J Oncol 34: 1247-1256.
22. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, et al. (2006) Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44: 240-251.
23. Liang CC, Park AY, Guan JL, (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333.
24. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
25. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
26. Repetto G, del Peso A, Zurita JL, (2008) Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 3: 1125-1131.
27. Lerche-Langrand C, Toutain HJ, (2000) Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology. Toxicology 153: 221-253.
28. Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, et al. (2005) TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. Embo J 24: 2458-2471.
29. Keum YS, Jeong WS, Kong AN, (2004) Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms. Mutat Res 555: 191-202.
30. Nakamura Y, (2009) Chemoprevention by isothiocyanates: molecular basis of apoptosis induction. Forum Nutr 61: 170-181.
31. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T, (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849.
32. Lowe SW, Ruley HE, Jacks T, Housman DE, (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
33. Strasser A, Harris AW, Jacks T, Cory S, (1994) DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79: 329-339.
34. Merritt AJ, Allen TD, Potten CS, Hickman JA, (1997) Apoptosis in small intestinal epithelial from p53-null mice: evidence for a delayed, p53-independent G2/M-associated cell death after gamma-irradiation. Oncogene 14: 2759-2766.
35. Clarke JD, Riedl K, Bella D, Schwartz SJ, Stevens JF, et al. (2011) Comparison of isothiocyanate metabolite levels and histone deacetylase activity in human subjects consuming broccoli sprouts or broccoli supplement. J Agric Food Chem 59: 10955-10963.
36. Fimognari C, Nusse M, Cesari R, Iori R, Cantelli-Forti G, et al. (2002) Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis 23: 581-586.
37. Gamet-Payrastre L, Li P, Lumeau S, Cassar G, Dupont MA, et al. (2000) Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 60: 1426-1433.
38. Choi S, Lew KL, Xiao H, Herman-Antosiewicz A, Xiao D, et al. (2007) D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1. Carcinogenesis 28: 151-162.
39. Jeng KS, Sheen IS, Chen BF, Wu JY, (2000) Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection? Arch Surg 135: 1329-1333.
40. Cengiz C, Akarca US, Goker E, Yuce G, (2003) Detection of mutant p53 in hepatocellular cancer from Turkey and its correlation with clinicopathologic parameters. Dig Dis Sci 48: 865-869.
41. Abbott A, (2006) Cancer: the root of the problem. Nature 442: 742-743.
42. Kallifatidis G, Labsch S, Rausch V, Mattern J, Gladkich J, et al. (2009) Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther 19: 188-195.
43. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, et al. (2010) Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 70: 5004-5013.
44. Li SH, Fu J, Watkins DN, Srivastava RK, Shankar S, (2013) Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway. Mol Cell Biochem 373: 217-227.
45. Musk SR, Johnson IT, (1993) Allyl isothiocyanate is selectively toxic to transformed cells of the human colorectal tumour line HT29. Carcinogenesis 14: 2079-2083.
46. Musk SR, Stephenson P, Smith TK, Stening P, Fyfe D, et al. (1995) Selective toxicity of compounds naturally present in food toward the transformed phenotype of human colorectal cell line HT29. Nutr Cancer 24: 289-298.
47. Gamet-Payrastre L, Lumeau S, Gasc N, Cassar G, Rollin P, et al. (1998) Selective cytostatic and cytotoxic effects of glucosinolates hydrolysis products on human colon cancer cells in vitro. Anticancer Drugs 9: 141-148.
48. Bruggeman IM, Temmink JH, van Bladeren PJ, (1986) Glutathione- and cysteine-mediated cytotoxicity of allyl and benzyl isothiocyanate. Toxicol Appl Pharmacol 83: 349-359.
49. Temmink JH, Bruggeman IM, van Bladeren PJ, (1986) Cytomorphological changes in liver cells exposed to allyl and benzyl isothiocyanate and their cysteine and glutathione conjugates. Arch Toxicol 59: 103-110.
50. Mi L, Xiao Z, Veenstra TD, Chung FL, (2011) Proteomic identification of binding targets of isothiocyanates: A perspective on techniques. J Proteomics 74: 1036-1044.
51. Lamy E, Scholtes C, Herz C, Mersch-Sundermann V, (2011) Pharmacokinetics and pharmacodynamics of isothiocyanates. Drug Metab Rev 43: 387-407.
52. Huang ZZ, Chen C, Zeng Z, Yang H, Oh J, et al. (2001) Mechanism and significance of increased glutathione level in human hepatocellular carcinoma and liver regeneration. Faseb J 15: 19-21.